高级检索
当前位置: 首页 > 详情页

Therapeutic effects of tetrahedral framework nucleic acids and tFNAs-miR22 on retinal ischemia/reperfusion injury

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Ophthalmology, and Research Laboratory of Macular Disease, West China Hospital, Sichuan University, Chengdu, China. [2]Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China. [3]National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu, China. [4]State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Department of Maxillofacial Surgery, West China Stomatological Hospital, Sichuan University, Chengdu, China.
出处:
ISSN:

摘要:
Retinal ischemia/reperfusion injury (RI/R) is a common pathological process in ophthalmic diseases, which can cause severe visual impairment. The mechanisms underlying RI/R damage and repair are still unclear. Scholars are actively exploring effective intervention strategies to restore impaired visual function. With the development of nucleic acid nanomaterials, tetrahedral framework nucleic acids (tFNAs) have shown promising therapeutic potential in various fields such as stem cells, biosensors, and tumour treatment due to their excellent biological properties. Besides, miRNA-22-3p (miR-22), as an important regulatory factor in neural tissue, has been proven to have positive effects in various neurodegenerative diseases. By stably constructing a complex of tetrahedral framework nucleic acids miR22 (tFNAs-miR22), we observed that tFNAs-miR22 had a positive effect on the repair of RI/R injury in retinal neural tissue. Previous studies have shown that tFNAs can effectively deliver miR-22 into damaged retinal neurons, subsequently exerting neuroprotective effects. Interestingly, we found that there was a certain synergistic effect between tFNAs and miR-22. tFNAs-miR22 can selectively activated the ERK1/2 signalling pathway to reduce neuronal apoptosis, accelerate cell proliferation, and restore synaptic functional activity. In this study, we established a simple yet effective small molecule drug for RI/R treatment which may become a promising neuroprotectant for treating this type of vision impairment disease in the future.© 2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 1 区 生物学
小类 | 2 区 细胞生物学
最新[2023]版:
大类 | 1 区 生物学
小类 | 2 区 细胞生物学
第一作者:
第一作者机构: [1]Department of Ophthalmology, and Research Laboratory of Macular Disease, West China Hospital, Sichuan University, Chengdu, China. [2]Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
共同第一作者:
通讯作者:
通讯机构: [1]Department of Ophthalmology, and Research Laboratory of Macular Disease, West China Hospital, Sichuan University, Chengdu, China. [*1]Department of Ophthalmology, and Research Laboratory of Macular Disease, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号